Mexico Prostate Cancer Drugs Market Analysis

Mexico Prostate Cancer Drugs Market Analysis


$ 3999

Mexico Prostate Cancer Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Prostate Cancer Drugs market is growing globally due to the increasing incidence and prevalence of prostate cancer in men globally, aging population, technological advancements in diagnostics improvements in imaging techniques like multiparametric magnetic resonance imaging (mpMRI), prostate-specific antigen (PSA) tests, and the development of new biomarkers, growing awareness about the disease, improvements in healthcare expenditure and emergence of strong pipeline drugs. Johnson & Johnson Private Limited, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC. and Genentech, Inc. are the key global market players in prostate cancer drugs market.

ID: IN10MXPH385 CATEGORY: Pharmaceuticals GEOGRAPHY: Middle East AUTHOR: Vidhi Upadhyay

Buy Now

Mexico Prostate Cancer Drugs Market Analysis Summary

Mexico Prostate Cancer Drugs Market is valued at around $167.5 Mn in 2022 and is projected to reach $326 Mn by 2030, exhibiting a CAGR of 8.68% during the forecast period 2023-2030.

A form of cancer known as prostate cancer occurs when abnormal cells in the prostate gland grow and uncontrollably enlarge. The tenth leading cause of mortality overall and the sixth major cause of death in men is prostate cancer. Treatments for prostate cancer include surgery, hormone therapy, radiation, chemotherapy, and biological therapy. Prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and other diagnoses and treatments are used to treat and manage prostate cancer. Prostate cancer in its early stages could not show any signs at all. The following signs and symptoms could appear as the illness worsens a lot of times which are frequent urination, especially at night, initiating and ending urinating with difficulty, insufficient or irregular urine flow, pee or sperm with blood in them, discomfort or pain in the pelvic region, erectile dysfunction. Johnson & Johnson Private Limited, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC. and Genentech, Inc. are the key global market players in prostate cancer drugs market.

Market Dynamics

Market Growth Drivers

Increasing incidence and prevalence of prostate cancer in men globally, the aging population, technological advancements in diagnostics improvements in imaging techniques like multiparametric magnetic resonance imaging (mpMRI), prostate-specific antigen (PSA) tests, and the development of new biomarkers, growing awareness about the disease, improvements in healthcare expenditure and the emergence of strong pipeline drugs. All these factors act as market growth drivers.

Market Restraints

High Cost of Treatment, Side Effects, and toxicities like urinary incontinence, erectile dysfunction, bowel dysfunction, hot flashes, fatigue, and increased risk of cardiovascular events. Resistance to treatment over time and disease progression, developing and obtaining regulatory approvals for new prostate cancer treatments can be a complex and lengthy process. All these factors act as market growth restraints.

Competitive Landscape

Key Players

  • Johnson & Johnson Private Limited
  • Astellas Pharma Inc.
  • Ipsen Pharma
  • Sanofi
  • Bayer AG
  • AbbVie Inc.
  • AstraZeneca
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Abbott
  • Takeda Pharmaceutical Company Limited.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Myovant Sciences GmbH
  • Tolmar Pharmaceuticals, Inc.
  • Ferring B.V.
  • Dendreon Pharmaceuticals LLC.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Mexico Prostate Cancer Drugs Market

By Drug Class

  • Hormonal Therapy
  • chemotherapy
  • Immunotherapy
  • Targeted Therapy

By End-Users

  • Clinics
  • Hospital
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up